Muthiah Manoharan

Active 1989–2025

102
Papers
36,138
Citations
77
h-index
98
i10-index

Citations

Citations per year for Muthiah Manoharan1990: 1 citations1992: 1 citations1993: 2 citations1994: 4 citations1995: 1 citations1996: 8 citations1997: 14 citations1998: 11 citations1999: 28 citations2000: 19 citations2001: 24 citations2002: 35 citations2003: 34 citations2004: 38 citations2005: 105 citations2006: 227 citations2007: 348 citations2008: 425 citations2009: 541 citations2010: 490 citations2011: 565 citations2012: 559 citations2013: 446 citations2014: 448 citations2015: 435 citations2016: 426 citations2017: 382 citations2018: 471 citations2019: 1,101 citations2020: 1,356 citations2021: 1,394 citations2022: 1,360 citations2023: 1,345 citations2024: 1,987 citations2025: 1,163 citations2026: 29 citations1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,271 citing papers, 30.9% of this breakdownChina: 1,947 citing papers, 14.1% of this breakdownGermany: 749 citing papers, 5.4% of this breakdownUnited Kingdom: 664 citing papers, 4.8% of this breakdownCanada: 550 citing papers, 4% of this breakdownJapan: 468 citing papers, 3.4% of this breakdownItaly: 412 citing papers, 3% of this breakdownFrance: 363 citing papers, 2.6% of this breakdownIndia: 341 citing papers, 2.5% of this breakdownNetherlands: 316 citing papers, 2.3% of this breakdownAustralia: 315 citing papers, 2.3% of this breakdownSouth Korea: 292 citing papers, 2.1% of this breakdown
0%30.9%Other 22.6%

Fields

  • Biochemistry, Genetics and Molecular Biology71%
  • Medicine14.7%
  • Immunology and Microbiology5.2%
  • Materials Science3.2%
  • Neuroscience2.1%
  • Engineering1.3%
  • Other2.5%

Topics

  • RNA Interference and Gene Delivery16.3%
  • Advanced biosensing and bioanalysis techniques10.4%
  • MicroRNA in disease regulation8.7%
  • Circular RNAs in diseases3.3%
  • Cancer-related molecular mechanisms research3%
  • DNA and Nucleic Acid Chemistry2.6%
  • Other55.7%

Coauthors

All papers

Open in search
  1. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

    Authors: , , , , , , , , , , , , , , , , , - Nature Nanotechnology 2019 cited by 1,569

  2. Chemistry, structure and function of approved oligonucleotide therapeutics

    Authors: , - Nucleic Acids Research 2023 cited by 768

  3. Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**

    Authors: , , , , , , , , , , , , , , , , , , - Angewandte Chemie 2012 cited by 1,221

  4. Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Therapy 2010 cited by 1,215

  5. Rational design of cationic lipids for siRNA delivery

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Verbena Kosovrasti, William Cantley, Ying K. Tam, Muthiah Manoharan, Marco A. Ciufolini, Mark A. Tracy, Antonin de Fougerolles, Ian MacLachlan, Pieter R. Cullis, Thomas D. Madden, Michael J. Hope - Nature Biotechnology 2010 cited by 1,779

  6. Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Therapy 2013 cited by 619

  7. Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles

    Authors: , , , , , , , , , , , , , , , - Molecular Therapy — Nucleic Acids 2013 cited by 482

  8. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown

    Authors: , , , , , , , , - Nature Biotechnology 2015 cited by 661

  9. Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Chemical Society 2014 cited by 1,078

  10. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Róbert Langer, Daniel G. Anderson - Nature Biotechnology 2008 cited by 1,220

  11. Silencing of microRNAs in vivo with ‘antagomirs’

    Authors: , , , , , , - Nature 2005 cited by 3,971

  12. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lei Johnson, Yongfeng Jiang, Scott Lentini, Jason A. Gilbert, Tuyen Nguyen, Samantha Chigas, Sarah LeBlanc, Urjana Poreci, Anne Kasper, Arlin B. Rogers, Saeho Chong, Wendell Davis, Jessica E. Sutherland, Adam Castoreno, Stuart Milstein, Mark K. Schlegel, Ivan Zlatev, Klaus Charissé, Mark Keating, Muthiah Manoharan, Kevin Fitzgerald, Jing‐Tao Wu, Martin A. Maier, Vasant Jadhav - Nature Biotechnology 2022 cited by 245

  13. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery

    Authors: , , , , , , , , , , , , , , , , , , - Nature Nanotechnology 2012 cited by 1,172

  14. Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nucleic Acids Research 2020 cited by 277

  15. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity

    Authors: , , , , , , , , , , , , , , - Nature Communications 2018 cited by 266

  16. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nucleic Acids Research 2017 cited by 270

  17. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2004 cited by 2,187

  18. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates

    Authors: , , , , , , , , , , , , - Molecular Therapy 2018 cited by 308

  19. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors

    Authors: , , , , , , , , , , , , , , , , - Journal of Controlled Release 2023 cited by 91

  20. From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nucleic Acids Research 2022 cited by 90

  21. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs

    Authors: , , , , , , , , , , , , , - Nature Biotechnology 2007 cited by 965

  22. RNAi therapeutics: a potential new class of pharmaceutical drugs

    Authors: , , , - Nature Chemical Biology 2006 cited by 1,085

  23. RNAi-mediated gene silencing in non-human primates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2006 cited by 1,350

  24. Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver

    Authors: , , , , , , , , , , , , , , - Molecular Therapy 2009 cited by 349